RARA and acute promyelocytic leukemia: Because of the PML-RARA fusion gene, the standard of care for APL patients is to administer all-trans retinoic acid (ATRA), which induces differentiation of the promyelocytes and, in turn, resolves the acute phase of the disease (Douer et al., 2013; Mendez et al., 2018; Puccetti and Ruthardt, 2004; Tallman et al., 1997).